|
|||||
|
|
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non‐Small Cell Lung Cancer: First‐Line Therapy and Beyond |
|
| Authors: | Lee Pai‐Scherf Gideon M. Blumenthal Hongshan Li Sriram Subramaniam Pallavi S. Mishra‐Kalyani Kun He Hong Zhao Jingyu Yu Mark Paciga Kirsten B. Goldberg Amy E. McKee Patricia Keegan Richard Pazdur |
| Affiliation: | Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA |
| Abstract: | |
| Keywords: | Non‐small cell lung cancer Pembrolizumab EGFR protein, Human United States Food and Drug Administration |